Picture ConsulTech GmbH RnD Credit Germany 650x80px
Document › Details

Selvita S.A.. (8/31/16). "Press Release: Selvita Shows 31% Revenue Growth in H1 2016". Kraków.

Organisation Organisation Selvita S.A. (WSE:SLV)
  Group Selvita (Group)
Products Product drug discovery services
  Product 2 drug discovery

Selvita, the largest drug discovery company in Central and Eastern Europe, has experienced a dynamic revenue growth in the first half of 2016. Net revenues from sales (excluding grants) amounted to PLN 22.7 MM, resulting in a 31.4% growth compared to H1 2015 when the net revenues (excl. grants) amounted to PLN 17.2 MM.

The total revenues including grants amounted to PLN 28.5 MM, as compared to PLN 24.7 MM in H1 2015, indicating a 15.5% increase.

The Group’s net profit for H1 2016 amounted to PLN 0.3 MM compared to the net profit of PLN 3.3 MM achieved in H1 2015. In the reported period, Selvita was investing intensely in its research infrastructure and international business development presence. The company has also consistently conducted research activities as part of the internal oncology programes started in previous years, most of which, in accordance with the adopted accounting policy, are directly classified as costs.

Full version of the Selvita Consolidated Quarterly Report for H1 2016 is available at:

Record changed: 2019-04-26


Picture [iito] Plain Stupid Simple 650x80px

More documents for Selvita (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top